Rofecoxib administration to paediatric patients undergoing adenotonsillectomy

Abstract

Rofecoxib administration to paediatric patients undergoing T&A did not result in increased bleeding. Rofecoxib, however, was not found to decrease morphine use or improve pain scores prior to hospital discharge in T&A patients who received intraoperative morphine and acetaminophen.

Parecoxib sodium reduces the need for opioids after tonsillectomy in children: a double-blind placebo-controlled randomized clinical trial

“…19 This is probably because the oral formulation of rofecoxib has a delayed absorption, i.e., the time of peak effect is longer than that of parecoxib sodium, 21,22 and the researchers assessed the effect of rofecoxib on opioid consumption only in the PACU.…”

Adjuvant local anaesthetics in the epipharyngeal space in day-case adenoidectomy: A prospective, randomized, double-blind, placebo-controlled trial

“…Therefore we also used the Wong Á/Baker FACES pain rating scale to obtain an estimate of the paediatric patient's assessment of pain. The WongÁ/Baker FACES pain rating scale is an established method for paediatric pain measuring; it is therefore often used to validate other pain-scoring tools [17,18] and has been used before in paediatric otolaryngological studies [3,19].…”

Pain Management for the Hospitalized Pediatric Patient

“…For other groups of children, including children with hypercoagulability disorders, Moya-Moya disease, or Kawasaki's disease, COX-2 inhibitors probably should be avoided, pending further study. Postoperative analgesic trials with COX inhibitors in children have yielded mixed results [41,42]. For chronic administration for children and adolescents with arthritis who have experienced significant gastrointestinal bleeding, clinicians may consider prescribing either a COX-2 inhibitor, some the modified salicylates with relatively mild gastric effects, including salsalate, diflunisal, or choline-magnesium salicylate [43], or some of the NSAIDs with milder gastric effects, such as etodolac or nambutone, along with gastric protective interventions, including acid blockers, misoprostol, and sucralfate.…”